BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 19505856)

  • 21. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
    D'Avolio A; Simiele M; De Francia S; Ariaudo A; Baietto L; Cusato J; Fava C; Saglio G; Di Carlo F; Di Perri G
    J Pharm Biomed Anal; 2012 Feb; 59():109-16. PubMed ID: 22036594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
    Couchman L; Birch M; Ireland R; Corrigan A; Wickramasinghe S; Josephs D; Spicer J; Flanagan RJ
    Anal Bioanal Chem; 2012 Jun; 403(6):1685-95. PubMed ID: 22526649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
    Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
    J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
    Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
    Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
    J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
    Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
    Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
    Hsieh Y; Galviz G; Zhou Q; Duncan C
    Rapid Commun Mass Spectrom; 2009 May; 23(9):1364-70. PubMed ID: 19337981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Olorofim (F901318), a Novel Antifungal Drug, in Human Plasma and Serum.
    Müller C; Fietz C; Koehler P; Sibley G; Nforbugwe ACA; Streichert T; Wiesen MHJ
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.
    Vrobel I; Janečková H; Faber E; Bouchalová K; Mičová K; Friedecký D; Adam T
    Ther Drug Monit; 2016 Aug; 38(4):516-24. PubMed ID: 27414975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
    Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
    Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Thomas X
    Bull Cancer; 2007 Oct; 94(10):871-80. PubMed ID: 17964981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A; Giordano S
    Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.
    Jourdil JF; Tonini J; Stanke-Labesque F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar; 919-920():1-9. PubMed ID: 23384531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
    Titier K; Picard S; Ducint D; Teilhet E; Moore N; Berthaud P; Mahon FX; Molimard M
    Ther Drug Monit; 2005 Oct; 27(5):634-40. PubMed ID: 16175138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
    Poetto AS; Posocco B; Gagno S; Orleni M; Zanchetta M; Iacuzzi V; Canil G; Buzzo M; Montico M; Guardascione M; Basile D; Pelizzari G; Alberti M; Gerratana L; Puglisi F; Toffoli G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122985. PubMed ID: 34700133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Indications and current development of new targeted therapies in pediatric oncology].
    Leblond P; Geoerger B
    Bull Cancer; 2011 May; 98(5):527-39. PubMed ID: 21596652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
    Furlong MT; Agrawal S; Hawthorne D; Lago M; Unger S; Krueger L; Stouffer B
    J Pharm Biomed Anal; 2012 Jan; 58():130-5. PubMed ID: 21982905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics of tyrosine kinase inhibitors.
    van Erp NP; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
    Chahbouni A; den Burger JC; Vos RM; Sinjewel A; Wilhelm AJ
    Ther Drug Monit; 2009 Dec; 31(6):683-7. PubMed ID: 19865001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
    Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.